Lakefront Biotherapeutics American Depositary Shares
LKFT
38 hedge funds and large institutions have $543M invested in Lakefront Biotherapeutics American Depositary Shares in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
48% more capital invested
Capital invested by funds: $367M → $543M (+$176M)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
19% more funds holding
Funds holding: 32 → 38 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.69M |
| 3 |
DM
Deerfield Management
New York
|
+$6.56M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$6.42M |
| 5 |
O
OrbiMed
New York
|
+$6.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.5M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.19M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.96M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.64M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$547K |
LKFT Hedge Fund Activity: Q2 2016 in Review
38 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2016, worth a combined $543M — up 48% from $367M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LKFT positions and 4 closed out — a net gain of 6 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $16.8M. The largest seller was Goldman Sachs, cutting an estimated $2.5M.
- 38 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2016, up from 32 in Q1 2016.
- Funds reported $543M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2016, up 48% quarter-over-quarter.
- 10 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2016 and 4 closed out, a net change of +6 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2016 was Cormorant Asset Management, an estimated $16.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2016 was Goldman Sachs, an estimated $2.5M sold.
Based on aggregated 13F filings for Q2 2016.